- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr George Bakris Speaks About Increasing Minority Representation in CKD Trials
In the FIDELIO-DKD trial researchers purposely recruited centers that had very large African American databases, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.
In the FIDELIO-DKD trial researchers purposely recruited centers that had very large African American databases, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.
Transcript
In FIDELIO-DKD, only 4.7% of patients identified themselves as Black. Is the FIGARO-DKD trial more diverse?
The FIGARO trial is going to be similar to the FIDELIO trial. Let me just make a point. For the audience listening, if you remember the African American Study of Kidney Disease, I was one of the principal investigators and writers of that study. That was a study of pure African Americans, over 1094 African Americans. There were very many African American investigators in that trial. It took an act of God to recruit that trial. African Americans don't willingly come to clinical trials for a variety of reasons. I made it a major point, as a principal investigator, to try to get at least 10% African Americans in the [FIDELIO] trial. We purposely recruited centers that had very large African American databases, so that we could recruit. And yet we ended up with this. So it's not that we didn't try. It's not that we don't appreciate it. It's just that it's very difficult to do. Having said that, looking at the database, the trends in the African Americans were very similar to the trends seen in the overall population. So that is gratifying.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
